TipRanks
Advertisement
Advertisement

MX:GILD Stock Latest News

Gilead announces agreement with PAHO for lenacapavir access
The FlyGilead announces agreement with PAHO for lenacapavir access
19h ago
GILD
Gilead price target raised to $175 from $155 at HSBC
PremiumThe Fly
Gilead price target raised to $175 from $155 at HSBC
6d ago
GILD
Assembly Biosciences exercises profit share option with Gilead for HSV program
PremiumThe Fly
Assembly Biosciences exercises profit share option with Gilead for HSV program
8d ago
ASMB
GILD
Gilead’s Bixlenvo approved by FDA for virologically suppressed adults with HIV
PremiumThe Fly
Gilead’s Bixlenvo approved by FDA for virologically suppressed adults with HIV
19d ago
GILD
Lakefront Biotherapeutics granted orphan drug designation for gamgertamig
PremiumThe Fly
Lakefront Biotherapeutics granted orphan drug designation for gamgertamig
23d ago
GILD
LKFT
Gilead says EC grants marketing authorization for Trodelvy/Keytruda combination
PremiumThe FlyGilead says EC grants marketing authorization for Trodelvy/Keytruda combination
23d ago
MRK
GILD
MacroGenics receives $10M milestone after Gilead exercises license option
Premium
The Fly
MacroGenics receives $10M milestone after Gilead exercises license option
30d ago
GILD
MGNX
Gilead Sciences Earnings Call Highlights Strong Core Growth
Premium
Company Announcements
Gilead Sciences Earnings Call Highlights Strong Core Growth
1M ago
GILD
Gilead: Strong HIV and Oncology Growth Underpins Reiterated Buy Rating and Unchanged $165 Price Target
PremiumRatings
Gilead: Strong HIV and Oncology Growth Underpins Reiterated Buy Rating and Unchanged $165 Price Target
1M ago
GILD
Gilead files automatic mixed securities shelf
PremiumThe Fly
Gilead files automatic mixed securities shelf
1M ago
GILD
Gilead price target lowered to $150 from $156 at Truist
PremiumThe Fly
Gilead price target lowered to $150 from $156 at Truist
1M ago
GILD
Gilead: Buy Rating Reaffirmed on Strong Fundamentals and HIV Franchise Momentum; $165 Price Target Maintained
PremiumRatings
Gilead: Buy Rating Reaffirmed on Strong Fundamentals and HIV Franchise Momentum; $165 Price Target Maintained
1M ago
GILD
Gilead price target raised to $123 from $120 at RBC Capital
PremiumThe FlyGilead price target raised to $123 from $120 at RBC Capital
1M ago
GILD
Gilead Buy Rating Reaffirmed on Strong HIV-Driven Growth and Raised Revenue Outlook; $170 Price Target Maintained
Premium
Ratings
Gilead Buy Rating Reaffirmed on Strong HIV-Driven Growth and Raised Revenue Outlook; $170 Price Target Maintained
1M ago
GILD
Gilead Sciences: Strong Core Performance and Upgraded HIV Outlook Underpin Buy Rating and Earnings Power
Premium
Ratings
Gilead Sciences: Strong Core Performance and Upgraded HIV Outlook Underpin Buy Rating and Earnings Power
1M ago
GILD
Gilead reports Q2 adjusted EPS ($6.75), consensus ($7.25)
PremiumThe Fly
Gilead reports Q2 adjusted EPS ($6.75), consensus ($7.25)
1M ago
GILD
Gilead raises FY26 EPS view to (65c)-(30c) from ($1.05)-(65c), consensus (75c)
PremiumThe Fly
Gilead raises FY26 EPS view to (65c)-(30c) from ($1.05)-(65c), consensus (75c)
1M ago
GILD
Gilead update on California ruling removes an overhang, says UBS
PremiumThe Fly
Gilead update on California ruling removes an overhang, says UBS
1M ago
GILD
Is GILD a Buy, Before Earnings?
PremiumPre-Earnings
Is GILD a Buy, Before Earnings?
2M ago
GILD
Michael Yee Reiterates Buy on Gilead, Citing Long-Acting HIV Pipeline and PrEP Advancements as Drivers of Durable Growth
PremiumRatingsMichael Yee Reiterates Buy on Gilead, Citing Long-Acting HIV Pipeline and PrEP Advancements as Drivers of Durable Growth
2M ago
GILD
Gilead price target lowered to $145 from $155 at Barclays
Premium
The Fly
Gilead price target lowered to $145 from $155 at Barclays
2M ago
GILD
Gilead price target lowered to $165 from $166 at Morgan Stanley
Premium
The Fly
Gilead price target lowered to $165 from $166 at Morgan Stanley
2M ago
GILD

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >